mProX™ Human EPHA2 Stable Cell Line

Sub Cat	Product Name	Target Protein Species	Host Cell Type	Assay Types	Inquiry	Datasheet
S01YF-1122-KX1123	Magic™ Human EPHA2 in Vitro Assay	Human		Kinase Assay

Product Information

Target Protein

EPHA2

Target Family

Kinases/Enzyme Drug Discovery Assays and Products

Target Protein Species

Human

Host Cell Type

MDA-MB-231; BT549; HCC1395; HCC1937; HCC1806; HBL-100; CHO-K1; HEK293

Target Classification

Kinase Cell Lines

Target Research Area

Ocular Research

Related Diseases

Cataract 6, Multiple Types and Cataract. Among its related pathways are GPCR Pathway and ERK Signaling

Gene ID

1969

UniProt ID

P29317

Product Properties

Biosafety Level

Level 1

Activity

Yes

Quantity

10⁶ cells per vial

Applications

The EPHA2 gene in humans encodes the protein known as EPH receptor A2 (ephrin type-A receptor 2). This gene is a member of the protein-tyrosine kinase family's ephrin receptor subfamily. Developmental events have been linked to EPH and EPH-related receptors, especially in the nervous system. The extracellular region of receptors in the EPH subfamily usually has two repeats of fibronectin type III and a Cys-rich domain, in addition to a single kinase domain. Based on the similarity of their extracellular domain sequences and their propensity to bind ephrin-A and ephrin-B ligands, the ephrin receptors are classified into two classes. A protein that binds ephrin-A ligands is encoded by this gene. The customized EPHA2 stable cell line can be used in antibody discovery and development, potential drug candidate screening and signaling pathway researches.

Protocols

Please visit our protocols page.

Customer Reviews

chat Amy

The EPHA2 cell line design is well-optimized, and the provided documentation is comprehensive. It has saved me time and effort compared to traditional methods. Mar 02 2023

chat Verified Customer

chat Stephanie

Most importantly, I would recommend this product to anyone who wants to research EPHA2. Aug 20 2023

chat Verified Customer

FAQ

Any questions about our products? Please visit our frequently asked questions page.

Published Data

Fig.1 EphA2 knockdown impairs proliferation in human TNBC cell lines.

Stable short hairpin RNA (shRNA) knockdown sublines were created in six different human TNBC lines in order to ascertain the function of EphA2 in TNBC. Immunoblot analysis showed that shEphA2 lines had>90% knockdown.

Ref: Song, Wenqiang, et al. "Targeting EphA2 impairs cell cycle progression and growth of basal-like/triple-negative breast cancers." Oncogene 36.40 (2017): 5620-5630.

Pubmed: 28581527

DOI: 10.1038/onc.2017.170

Research Highlights

Additionally, this review highlights the potential and difficulties of targeting EphA2 in cancer by summarizing finished and continuing clinical trials.
Wilson, Kalin, Eileen Shiuan, and Dana M. Brantley-Sieders. "Oncogenic functions and therapeutic targeting of EphA2 in cancer." Oncogene 40.14 (2021): 2483-2495.
Pubmed: 33686241 DOI: 10.1038/s41388-021-01714-8

Within the subfamily of receptor tyrosine kinases, the Eph (erythropoietin-producing human hepatocellular) receptors are the largest. Direct cell-to-cell contacts between these receptors and membrane-bound ephrin ligands cause the bidirectional activation of signal pathways.
London, Max, and Eugenio Gallo. "The EphA2 and cancer connection: potential for immune-based interventions." Molecular Biology Reports 47 (2020): 8037-8048.
Pubmed: 32990903 DOI: 10.1007/s11033-020-05767-y